Advances of immune-vascular crosstalk for oncology therapeutics / 中国药理学通报

ABSTRACT

Malignant tumor is one of the important reasons threatening human health and safety at present. The application of antiangiogenic drugs and immune checkpoint inhibitors has brought great hope for tumor treatment, but the complex interlaced relationship between tumor blood vessels and immune microenvironment leads to unsatisfactory efficacy. In addition,VEGF, a key driver of tumor angiogenesis, interferes with the maturation of dendritic cells, thereby inhibiting the initiation of T cells. VEGF also induces depletion of CD8+T cells. At the same time, various innate and acquired immune cells secrete angiogenic factors that accelerate uncontrolled angiogenesis and promote vascular immaturity. Therefore targeting tumor blood vessels and immunity is a potential strategy for enhancing tumor immunotherapy. In recent years numerous studies have found that using the blood vessels and the immune intervention strategies combined with antitumor immune therapy has achieved good results. In this review the immune and vascularized tumor microenvironment are reviewed and discussed, and the research progress of vascularized immune interintervention strategy for tumor treatment in recent years is reviewed so as to provide reference for further improving the efficacy of tumor immunotherapy.